An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation

Cancer Letters

Volumn 322, Issue 1, 2012, Pages 45-57

  Lee, Bok Soon ^a,b   Kang, Sung Un ^a,b   Hwang, Hye Sook ^a,b   Kim, Yong Sung ^a,b   Sung, Eun Sil ^a,b   Shin, Yoo Seob ^a,b   Lim, Young Chang ^c   Kim, Chul Ho ^a,b  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

Author keywords

Agonistic antibody; Apoptosis; Death receptor 4; Head and neck cancer; ROS

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; CASPASE; CELL PROTEIN; DEATH RECEPTOR 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AY4; PROTEIN BCL XL; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROTECTION; CELL STRAIN; CELL STRAIN FADU; CELL STRAIN HN9; CELL STRAIN KB; CELL STRAIN SNU899; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; EMBRYO; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MALE; MITOCHONDRION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ZEBRA FISH;

ACETYLCYSTEINE; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; ZEBRAFISH;

DANIO RERIO; MUS MUSCULUS;

EID: 84862830496     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.007     Document Type: Article

References (52)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59(2009):225-249.
2. Argiris A., Karamouzis M.V., Raben D., Ferris R.L. Head and neck cancer. Lancet 2008, 371:1695-1709.
3. Forastiere A.A., Goepfert H., Maor M., Pajak T.F., Weber R., Morrison W., Glisson B., Trotti A., Ridge J.A., Chao C., Peters G., Lee D.J., Leaf A., Ensley J., Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl. J. Med. 2003, 349:2091-2098.
4. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996, 271:12687-12690.
5. Ashkenazi A., Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 2008, 118:1979-1990.
6. Lee C.H., Park K.J., Sung E.S., Kim A., Choi J.D., Kim J.S., Kim S.H., Kwon M.H., Kim Y.S. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2010, 107:9567-9571.
7. Marini P., Junginger D., Stickl S., Budach W., Niyazi M., Belka C. Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions. Radiat. Oncol. 2009, 4:49.
8. Wei M.C., Lindsten T., Mootha V.K., Weiler S., Gross A., Ashiya M., Thompson C.B., Korsmeyer S.J. TBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes. Dev. 2000, 14:2060-2071.
9. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
10. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 2005, 55:178-194.
11. Kaufmann S.H., Vaux D.L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003, 22:7414-7430.
12. Niyazi M., Marini P., Daniel P.T., Humphreys R., Jendrossek V., Belka C. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin. Oncol. Rep. 2009, 21:1455-1460.
13. Yodkeeree S., Sung B., Limtrakul P., Aggarwal B.B. Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res. 2009, 69:6581-6589.
14. Prasad S., Yadav V.R., Ravindran J., Aggarwal B.B. ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res. 2011, 71:538-549.
15. Buttke T.M., Sandstrom P.A. Oxidative stress as a mediator of apoptosis. Immunol Today 1994, 15:7-10.
16. Goossens V., De Vos K., Vercammen D., Steemans M., Vancompernolle K., Fiers W., Vandenabeele P., Grooten J. Redox regulation of TNF signaling. Biofactors 1999, 10:145-156.
17. Chen C., Liu Y., Zheng D. An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells. Cell Res. 2009, 19:984-995.
18. Sung E.S., Park K.J., Lee S.H., Jang Y.S., Park S.K., Park Y.H., Kwag W.J., Kwon M.H., Kim Y.S. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Mol. Cancer Ther. 2009, 8:2276-2285.
19. Sung E.S., Kim A., Park J.S., Chung J., Kwon M.H., Kim Y.S. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 2010, 15:1256-1269.
20. Kim S.Y., Chu K.C., Lee H.R., Lee K.S., Carey T.E. Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol. 1997, 117:775-784.
21. Lim Y.C., Park H.Y., Hwang H.S., Kang S.U., Pyun J.H., Lee M.H., Choi E.C., Kim C.H. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett. 2008, 271:140-152.
22. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104:155-162.
23. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 2001, 7:383-385.
24. Ozoren N., Fisher M.J., Kim K., Liu C.X., Genin A., Shifman Y., Dicker D.T., Spinner N.B., Lisitsyn N.A., El-Deiry W.S. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol. 2000, 16:917-925.
25. Kim H.J., Hawke N., Baldwin A.S. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006, 13:738-747.
26. Ren X., Xu Z., Myers J.N., Wu X. Bypass NFkappaB-mediated survival pathways by TRAIL and Smac. Cancer Biol. Ther. 2007, 6:1031-1035.
27. Fisher M.J., Virmani A.K., Wu L., Aplenc R., Harper J.C., Powell S.M., Rebbeck T.R., Sidransky D., Gazdar A.F., El-Deiry W.S. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 2001, 7:1688-1697.
28. Kim K., Fisher M.J., Xu S.Q., el-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000, 6:335-346.
29. Hinz S., Trauzold A., Boenicke L., Sandberg C., Beckmann S., Bayer E., Walczak H., Kalthoff H., Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19:5477-5486.
30. Kandasamy K., Srinivasula S.M., Alnemri E.S., Thompson C.B., Korsmeyer S.J., Bryant J.L., Srivastava R.K. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. 2003, 63:1712-1721.
31. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., Fong S., Schwall R., Sinicropi D., Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 2002, 8:274-281.
32. Rippo M.R., Moretti S., Vescovi S., Tomasetti M., Orecchia S., Amici G., Catalano A., Procopio A. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2004, 23:7753-7760.
33. Ricci M.S., Jin Z., Dews M., Yu D., Thomas-Tikhonenko A., Dicker D.T., El-Deiry W.S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol. 2004, 24:8541-8555.
34. Cadenas E., Davies K.J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med. 2000, 29:222-230.
35. Cerutti P.A. Prooxidant states and tumor promotion. Science 1985, 227:375-381.
36. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
37. Song J.J., An J.Y., Kwon Y.T., Lee Y.J. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J. Biol. Chem. 2007, 282:319-328.
38. Shi R.X., Ong C.N., Shen H.M. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res. 2005, 65:7815-7823.
39. Silke J., Kratina T., Ekert P.G., Pakusch M., Vaux D.L. Unlike diablo/smac, grim promotes global ubiquitination and specific degradation of X chromosome-linked inhibitor of apoptosis (XIAP) and neither cause apoptosis. J. Biol. Chem. 2004, 279:4313-4321.
40. Bank A., Yu J., Zhang L. NSAIDs downregulate Bcl-X(L) and dissociate BAX and Bcl-X(L) to induce apoptosis in colon cancer cells. Nut. Cancer 2008, 60(Suppl 1):98-103.
41. Izeradjene K., Douglas L., Tillman D.M., Delaney A.B., Houghton J.A. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res. 2005, 65:7436-7445.
42. Moungjaroen J., Nimmannit U., Callery P.S., Wang L., Azad N., Lipipun V., Chanvorachote P., Rojanasakul Y. Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation. J. Pharmacol. Exp. Ther. 2006, 319:1062-1069.
43. Lee Y.J., Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J. Biol. Chem. 1999, 274:19792-19798.
44. Choi K., Ryu S.W., Song S., Choi H., Kang S.W., Choi C. Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ. 2010, 17:833-845.
45. Laurent A., Nicco C., Chereau C., Goulvestre C., Alexandre J., Alves A., Levy E., Goldwasser F., Panis Y., Soubrane O., Weill B., Batteux F. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005, 65:948-956.
46. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl. J. Med. 2006, 354:567-578.
47. Luo F.R., Yang Z., Dong H., Camuso A., McGlinchey K., Fager K., Flefleh C., Kan D., Inigo I., Castaneda S., Rose W.C., Kramer R.A., Wild R., Lee F.Y. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol. 2005, 56:455-464.
48. Kamath A.V., Lu D., Gupta P., Jin D., Xiang H., Wong A., Leddy C., Crocker L., Schaefer G., Sliwkowski M.X., Damico-Beyer L.A. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol. 2011.
49. Marathe P.H., Kamath A.V., Zhang Y., D'Arienzo C., Bhide R., Fargnoli J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol. 2009, 65:55-66.
50. Eimon P.M., Ashkenazi A. The zebrafish as a model organism for the study of apoptosis. Apoptosis: An Int. J. Programm Cell Death 2010, 15:331-349.
51. Hymowitz S.G., O'Connell M.P., Ultsch M.H., Hurst A., Totpal K., Ashkenazi A., de Vos A.M., Kelley R.F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000, 39:633-640.
52. Pham C., Greenwood J., Cleland H., Woodruff P., Maddern G. Bioengineered skin substitutes for the management of burns: a systematic review. Burns 2007, 33:946-957.